1.Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer.
Huanlan SA ; Kewei MA ; Yong GAO ; Deqiang WANG
Chinese Journal of Lung Cancer 2019;22(6):380-384
The morbidity and mortality of lung cancer is the first in the world, immunotherapy has become a important treatment strategy in addition to chemotherapy, radiotherapy and targeted therapy. In recent years, the US Food and Drug Administration (FDA) has successively approved immunological checkpoint inhibitors as standard programs for non-small cell lung cancer (NSCLC) in second-line or first-line treatment. The National Comprehensive Cancer Network (NCCN) also recommends immunological checkpoint inhibitors as the standard treatment for small cell lung cancer (SCLC). Now, the treatment for lung cancer has entered the era of precision treatment, it is very important to select effective and reliable biomarker for the dominant populations of lung cancer to receive immunotherapy. A large number of researchs indicated that tumor mutation burden (TMB) may be an independent predicted biomarker for immunotherapy, but with limitations. This article reviewed the predictive value of TMB and its limitations in the field of immunotherapy for lung cancer.
Animals
;
Biomarkers
;
metabolism
;
Humans
;
Immunologic Factors
;
administration & dosage
;
Immunotherapy
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
Mutation
;
Tumor Burden
2.New Advances in the Treatment for Small Cell Lung Cancer.
Xiaoxia CUI ; Peng SONG ; Li ZHANG
Chinese Journal of Lung Cancer 2019;22(6):355-362
Small cell lung cancer (SCLC) is a refractory cancer with high degree of malignancy, rapid disease progression, poor prognosis and easy recurrence. In the past 30 years, the traditional treatment of SCLC, mainly chemotherapy and radiotherapy, has not changed significantly, and the effective treatment method for clinical needs is extremely urgent. The rapid development of precision medicine has revealed the molecular biological characteristics of SCLC, so its diagnosis and treatment will into a new era. At present, some studies have shown that anti-angiogenic drugs, immunotherapy and so on have improved the efficacy of SCLC treatment to some extent, and there are more studies on the diagnosis and treatment of SCLC, so a new field of SCLC treatment are coming and bringing more survival benefits to patients. New studies on targeted therapy, anti-angiogenesis drugs and immunotherapy of molecular pathology of SCLC are emerging. This paper reviews the new diagnosis and treatment methods of SCLC to provide new guidance for its clinical treatment.
.
Angiogenesis Inhibitors
;
administration & dosage
;
Animals
;
Humans
;
Immunologic Factors
;
administration & dosage
;
Immunotherapy
;
Lung Neoplasms
;
diagnosis
;
drug therapy
;
Small Cell Lung Carcinoma
;
diagnosis
;
drug therapy
3.Early recognition and intervention of primary immunodeficiency.
Chinese Journal of Pediatrics 2006;44(6):427-430
Child
;
China
;
epidemiology
;
Diagnosis, Differential
;
Early Diagnosis
;
Hematopoietic Stem Cell Transplantation
;
methods
;
Humans
;
Immunoglobulins, Intravenous
;
administration & dosage
;
pharmacology
;
Immunologic Deficiency Syndromes
;
diagnosis
;
epidemiology
;
prevention & control
;
therapy
;
Immunologic Factors
;
administration & dosage
;
pharmacology
;
Infant, Newborn
;
Neonatal Screening
4.Combined group A streptococcus preparation (sapylin) and cisplatin for malignant peritoneal effusion.
Chinese Journal of Oncology 2005;27(7):442-444
OBJECTIVETo evaluate the effect of Group A streptococcus preparation (sapylin) combined with cisplatin on the malignant peritoneal effusion in patients with advanced cancer.
METHODSSixty advanced cancer patients with large amount of peritoneal effusion were divided into two groups: sapylin + cisplatin (DDP) group (30 patients) and control group (DDP alone, 30 cases). All the chemotherapeutic agents were injected intraperitoneally through a catheter.
RESULTSIn sapylin + cisplatin(DDP) group, 11 (36.7%) patients showed CR and 16 (53.3%) PR. The overall response rate (CR + PR) was 90.0%. Those of DDP alone group were 16.7% and 46.7%, the overall response rate was 63.3%. The main adverse effects were fever, nausea, and vomiting.
CONCLUSIONCombined Group A streptococcus preparation (sapylin) and cisplatin is more effective than cisplatin alone for the malignant peritoneal effusion in patients with advanced cancer, and the adverse effects are tolerable.
Adjuvants, Immunologic ; administration & dosage ; Adult ; Aged ; Antineoplastic Agents ; administration & dosage ; Ascitic Fluid ; pathology ; Bacterial Proteins ; administration & dosage ; Biological Products ; administration & dosage ; Cisplatin ; administration & dosage ; Combined Modality Therapy ; Female ; Humans ; Immunologic Factors ; administration & dosage ; Injections, Intraperitoneal ; Male ; Middle Aged ; Ovarian Neoplasms ; pathology ; therapy ; Peritoneal Neoplasms ; secondary ; therapy ; Stomach Neoplasms ; pathology ; therapy ; Streptococcus pyogenes ; chemistry
5.Aureobasidium-Derived Soluble Branched (1,3-1,6) beta-Glucan (Sophy beta-glucan) Enhances Natural Killer Activity in Leishmania amazonensis-Infected Mice.
Lalani YATAWARA ; Susiji WICKRAMASINGHE ; Mitsuru NAGATAKI ; Misa TAKAMOTO ; Haruka NOMURA ; Yasunori IKEUE ; Yoshiya WATANABE ; Takeshi AGATSUMA
The Korean Journal of Parasitology 2009;47(4):345-351
The beta-glucans derived from yeast cell walls have been reported for having many immunomodulatory activities in vivo and in vitro. In this study, Aureobasidium-derived soluble branched (1,3-1,6) beta-glucan (Sophy beta-glucan) was checked for natural killer (NK) activity and for the production of IFN-gamma and IL-4 in Leishmania amazonensis infection. The main experiment was performed with a group of female C57BL/6 and BALB/c mice, orally supplemented with 5% of Sophy beta-glucan and infected with promastogotes of L. amazonensis (1 x 10(7)) into the footpad. Increase in the footpad thickness with time was observed in BALB/c mice in spite of the oral Sophy beta-glucan supplement, but it was less in C57BL/6 mice. The difference in overall mean footpad thickness between 'infection only' versus 'infection + glucan' groups was statistically significant (P < 0.001). High NK activity in C57BL/6 than BALB/c mice was observed in 'glucan only' group compared to the control group and also in 'infection + glucan' group compared to 'infection only' group. The difference in the NK activity among these groups was significant (P < 0.05). The IFN-gamma level increased at weeks 7 and 8 post-infection in C57BL/6 mice and was significantly high in 'infection + glucan' group compared to the 'infection only' group (P < 0.05). IL-4 levels did not increase up to detectable levels throughout the study. The results led a conclusion that Sophy beta-glucan enhances NK activity and cellular immunity in L. amazonensis-infected mice.
Administration, Oral
;
Animals
;
Ascomycota/*chemistry
;
Cytotoxicity Tests, Immunologic
;
Female
;
Foot/pathology
;
Glucans/administration & dosage/*isolation & purification/pharmacology/*therapeutic use
;
Immunologic Factors/administration & dosage/*isolation & purification/pharmacology/*therapeutic use
;
Interferon-gamma/biosynthesis
;
Interleukin-4/biosynthesis
;
Killer Cells, Natural/drug effects/*immunology
;
Leishmania mexicana/*immunology
;
Leishmaniasis, Cutaneous/*drug therapy/immunology/pathology
;
Mice
;
Mice, Inbred BALB C
;
Mice, Inbred C57BL
;
Severity of Illness Index
;
Time Factors
6.Evolution of Myelofibrosis Treatment.
Korean Journal of Medicine 2016;90(4):293-297
Myelofibrosis (MF) is a classical Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal proliferation of pluripotent stem cells, dysfunctional kinase signaling, and abnormal cytokine release. MF is a heterogeneous disease, ranging from asymptomatic to being associated with one or more of the following problems: profound anemia, splenomegaly, constitutional issues, and even rapid progression to overt leukemia. Recently, important progress has been made. A Janus kinase (JAK) 2 mutation affects both pathogenesis and prognosis. Conventional treatment is primarily palliative and has only limited effects on the natural course of the disease. Allogeneic stem cell transplantation is the only curative treatment, but is presently limited to eligible intermediate-2 and high-risk patients. Ruxolitinib, the first drug approved by the Food and Drug Administration for treatment of intermediate-2 and high-risk patients, is currently the best available therapy for symptomatic MF patients. Additional JAK inhibitors are under investigation. Emerging therapies include immunomodulators and inhibitors of histone deacetylase (HDAC), mammalian target of rapamycin (mTOR), and telomerase. A better understanding of disease pathogenesis will lead to the development of better treatments modifying the disease course and, ultimately, curing the condition.
Anemia
;
Histone Deacetylases
;
Humans
;
Immunologic Factors
;
Leukemia
;
Phosphotransferases
;
Pluripotent Stem Cells
;
Primary Myelofibrosis*
;
Prognosis
;
Sirolimus
;
Splenomegaly
;
Stem Cell Transplantation
;
Telomerase
;
United States Food and Drug Administration
7.Immunomodulatory function of orally administered thymosin alpha1.
Xiang-Ming CHEN ; Han-Liang JIANG ; Lin-Fu ZHOU ; Xiao-Ping PAN ; Zhong-Rong HU ; Rong-Hua LIU ; Xiao-Ming CHEN ; Zhi CHEN
Journal of Zhejiang University. Science. B 2005;6(9):873-876
OBJECTIVETo investigate the immunological function of a yeast expression system for thymosin alpha1 (Talpha1).
METHODSA constructed Talpha1 yeast expression system was used to investigate the immunological function of orally administered Talpha1. Dried yeast containing three different concentration of Talpha1 was fed to normal Balb/c mice and other Balb/c mice whose immunities were inhibited in advance by cyclophosphamide. Synthesized Talpha1 peptide was used as positive control and dried yeast with empty plasmid was used as negative control. CD4(+) and CD8(+) levels were detected by flow cytometry assay. TNF-alpha, IFN-gamma, IL-2, IL-6 and IL-10 levels were detected by liquid chip.
RESULTSIn normal Balb/c mice or immune inhibition Balb/c mice, CD8(+) levels were significantly increased. Especially in immune inhibition Balb/c mice, CD8(+) levels in synthesized Talpha1 group (18.77%+/-4.72%), small dose group (13.48%+/-6.17%) and large dose group (22.74%+/-1.09%) were significantly higher than that in empty yeast control group (7.49%+/-2.14%).
CONCLUSIONOrally administered Talpha1 has its certain immunomodulatory function.
Administration, Oral ; Animals ; CD4-Positive T-Lymphocytes ; drug effects ; CD8-Positive T-Lymphocytes ; drug effects ; Cyclophosphamide ; toxicity ; Cytokines ; metabolism ; Immunologic Deficiency Syndromes ; chemically induced ; drug therapy ; immunology ; Immunologic Factors ; administration & dosage ; genetics ; Immunosuppressive Agents ; toxicity ; Mice ; Mice, Inbred BALB C ; Recombinant Proteins ; administration & dosage ; genetics ; Saccharomyces cerevisiae ; genetics ; Thymosin ; administration & dosage ; analogs & derivatives
8.Clinical study of early interventions for ABO hemolytic disease of the newborn.
Wei-min HUANG ; Hong-wu CHEN ; Ning LI ; Ming YANG ; Pei-yan JIAO
Journal of Southern Medical University 2006;26(9):1350-1355
OBJECTIVETo investigate therapeutic effect of high-dose intravenous immunoglobulin (IVIG) for early management of ABO hemolytic disease of the newborn (ABO-HDN).
METHODSA total of 121 cases with ABO-HDN were randomly divided into treatment group (n=61) and control group (n=60). In addition to the routine treatment of the control group, IVIG were given at a daily dose of 400 mg/kg to the cases in the treatment group for 2-3 times, and therapeutic effects were evaluated and compared between the two groups.
RESULTSThe serum total billirubin concentration on the third day after treatment (153.42-/+45.21 micromol/L) and mean daily serum total billirubin concentration reduction (56.49-/+24.05 micromol/L) in treatment group were lower than those in the control group (P<0.01). The jaundice resolution time (23.51-/+11.19 h) and the phototherapy time (3.01-/+0.89 h) for billirubinemia treatment in treatment group were shorter than those in the control group (P<0.01). The patients in the the treatment group had higher hemoglobin level after treatment (15.59-/+2.01 g/L) than those of the control group (P<0.01).
CONCLUSIONHigh-dose IVIG can effectively arrest the progression of hemolytic disease, quickly reduce serum total billirubin concentration and shorten phototherapy time for early treatment of ABO-HDN.
ABO Blood-Group System ; Bilirubin ; blood ; Erythroblastosis, Fetal ; blood ; drug therapy ; immunology ; Female ; Humans ; Immunoglobulins, Intravenous ; administration & dosage ; therapeutic use ; Immunologic Factors ; administration & dosage ; therapeutic use ; Infant, Newborn ; Jaundice, Neonatal ; drug therapy ; Male ; Time Factors ; Treatment Outcome
9.Current status and prospect of neoplasm targeted therapy.
Chinese Journal of Oncology 2005;27(10):638-640
Antibodies, Monoclonal
;
administration & dosage
;
Antibodies, Monoclonal, Humanized
;
Antineoplastic Agents
;
administration & dosage
;
Benzamides
;
Cetuximab
;
Drug Delivery Systems
;
methods
;
Drug Design
;
Erlotinib Hydrochloride
;
Humans
;
Imatinib Mesylate
;
Immunologic Factors
;
administration & dosage
;
Neoplasms
;
drug therapy
;
Palliative Care
;
methods
;
Piperazines
;
administration & dosage
;
Pyrimidines
;
administration & dosage
;
Quinazolines
;
administration & dosage
;
Signal Transduction
10.Current state of diagnosis and treatment of incomplete Kawasaki disease.
Chinese Journal of Pediatrics 2006;44(5):339-341
Child, Preschool
;
Coronary Aneurysm
;
diagnosis
;
etiology
;
prevention & control
;
Diagnosis, Differential
;
Early Diagnosis
;
Humans
;
Immunoglobulins, Intravenous
;
administration & dosage
;
therapeutic use
;
Immunologic Factors
;
administration & dosage
;
therapeutic use
;
Infant
;
Mucocutaneous Lymph Node Syndrome
;
classification
;
complications
;
diagnosis
;
drug therapy
;
Prognosis